Dose accuracy of the follitropin alfa pen injector 2.0, the follitropin alfa:lutropin alfa 2:1 combination pen injector 2.0 and the choriogonadotropin alfa pen injector 1.0 used for fertility treatment-Reference-Cited by-同舟云学术

Dose accuracy of the follitropin alfa pen injector 2.0, the follitropin alfa:lutropin alfa 2:1 combination pen injector 2.0 and the choriogonadotropin alfa pen injector 1.0 used for fertility treatment

Published:2024-02 Issue: Volume: Page:1-10
ISSN:1742-5247
Container-title:Expert Opinion on Drug Delivery
language:en
Short-container-title:Expert Opinion on Drug Delivery

Author:

Cottell Evelyn¹,Michalet Damien²,Lispi Monica¹³,Araujo Thiago Dantas²,Gleixner Ralf²,Longobardi Salvatore⁴,D’Hooghe Thomas¹⁵⁶

Affiliation:

1. Merck Healthcare KGaA, Darmstadt, Germany

2. Ares Trading S.A. Eysins (An affiliate of Merck KGaA), Switzerland

3. School of Clinical and Experimental Medicine, Unit of Endocrinology, University of Modena and Reggio Emilia, Modena, MO, Italy

4. Global Clinical Development, Merck Serono S.p.A, Rome, Italy, an affiliate of Merck KGaA, Darmstadt, Germany

5. Department of Development and Regeneration, Laboratory of Endometrium, Endometriosis & Reproductive Medicine, KU Leuven, Leuven, Belgium

6. Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University Medical School, New Haven, CT, USA

Funder

Merck

Publisher

Informa UK Limited

Subject

Pharmaceutical Science

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425247.2024.2311127

Reference19 articles.

1. The Development of Gonadotropins for Clinical Use in the Treatment of Infertility

2. FDA. Highlights of prescribing information for gonal-f RFF redi-ject 2013 [cited 2022 Jan 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021684s036lbl.pdf

3. Dose accuracy of the redesigned follitropin alfa pen injector for infertility treatment

4. EMA. GONAL-f: summary of product characteristics. The Netherlands: European Medicines Agency. 2023 [cited 2023 Oct 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/gonal-f-epar-product-information_en.pdf

5. EMA. Ovitrelle: summary of product characteristics. The Netherlands: European Medicines Agency; 2021 [cited 2022 Jan 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/ovitrelle-epar-product-information_en.pdf